Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 11/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.44 |
| ▸ | WDR5 | P61964 | 1/20 | 0.43 |
| ▸ | HCK | P08631 | 1/20 | 0.43 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29368215 | 1.00 | HDAC3 (0.53) | HDAC3HDAC2KCNH2HDAC1NCOR2 | |
| SCHEMBL20181817 | 0.93 | GBA1 (0.47) | HDAC3HDAC2KCNH2HDAC1NCOR2 | |
| SCHEMBL21538675 | 0.93 | HDAC3 (0.56) | HDAC3HDAC2KCNH2HDAC1NCOR2 | |
| SCHEMBL21835794 | 0.90 | HDAC3 (0.56) | HDAC3HDAC2KCNH2HDAC1NCOR2 | |
| SCHEMBL24233469 | 0.86 | HDAC3 (0.71) | HDAC3HDAC2KCNH2HDAC1NCOR2 | |
| SCHEMBL29370819 | 0.86 | WDR5 (0.45) | HDAC3HDAC2KCNH2HDAC1WDR5 | |
| SCHEMBL24233451 | 0.86 | WDR5 (0.45) | HDAC3HDAC2KCNH2HDAC1WDR5 | |
| SCHEMBL20181696 | 0.85 | HDAC3 (0.72) | HDAC3HDAC2KCNH2HDAC1HCK | |
| SCHEMBL8232846 | 0.84 | HDAC3 (0.73) | HDAC3HDAC2KCNH2HDAC1 | |
| SCHEMBL23960955 | 0.84 | HDAC3 (0.59) | HDAC3HDAC2KCNH2HDAC1HCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858919-B2 | HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858919-B2 | HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20220033388-A1 | HDAC1,2 Inhibitors | REGENACY PHARMACEUTICALS, LLC | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858919-B2 | HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | HDAC3 6/4885HDAC2 2/4885KCNH2 4383/4885 |
| US-20220033388-A1 | HDAC1,2 Inhibitors | HDAC1, HDAC2, HDAC11 | HDAC3 6/4885HDAC2 2/4885KCNH2 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.